The pressure of increasing global production of monoclonal antibodies is being instrumented by their therapeutic advantages in multiple healthcare procedures. Research institutes and medical organizations across the globe are progressing towards development of effective monoclonal antibodies at feasible costs of production. Cell and tissue culture projects are being directed to test and estimate the use of certain proteins in cultivation of monoclonal antibodies. Chromatographic resins are being utilized for purifications process used in production of monoclonal antibodies. One of the most dynamic candidate being considered as the ideal chromatographic resin for purification of monoclonal antibodies is – protein A resin.
Research studies and clinical examination on procurement of monoclonal antibodies has deemed protein A resins beneficial for performing purification processes, serving cost-effectiveness and a highly-reusable chromatographic resin. Commercial-scale purification of monoclonal antibodies has been estimated to take place effectively when protein A resins are included as the sole chromatography ligands. The affinity of protein A resins as chromatography ligand helps in capturing antibodies in the initial stage of scientific procurement, which is why protein A resins are constituted in every monoclonal antibodies purification platform that has been devised in the world.
However, the limited capacity of protein A resin curbs the purification efficacy when the number of antibody titers are increased. Nevertheless, the economics of monoclonal antibodies purification is improved by the use of protein A resins that can repetitively withstand cleaning-in-place (CIP) and consume a low-cost sodium hydroxide during this process. Furthermore, genes used for protein A resins are also used for large-scale production of recombinant protein A. Innovative approach through advanced protein engineering also facilitates an enhanced production omonoclonal antibodies. Sanitization protocols upon which the purification of monoclonal antibodies takes place can be carried out cost-effectively through engineered protein A resins.
A recent study conducted by Future Market Insights estimates that more than US$ 350 million revenues were procured from global consumption of protein A resin in 2016. The study illustrates how the demand for protein A resins will remain higher in regions such as Western Europe, North America and Asia-Pacific (excluding Japan). Revenues amassed from these regions will account for over 70% of global protein A resin market.
According to the report, titled “Protein A Resin Market: Global Industry Analysis & Opportunity Assessment, 2016-2026,” monoclonal antibodies render a wide range of therapeutic applications, inducing greater biotechnological research. Growing expenditure on monoclonal antibody research brings in more profit for suppliers of protein A resins. Moreover, lowering production costs of protein A resins without impeding their quality will further boost the global market for protein A resin. The market, however, will witness a considerable plunge in terms of growth, if alternative purification process for monoclonal antibodies begin to gain traction in the years to come. High costs of protein A resin-based purification process will further inhibit the growth in global protein A resin revenues. In 2016, monoclonal antibody purification processes held the largest market share. Meanwhile, recombinant protein A resins accounted for revenues worth over US$ 135 million. In 2017 and beyond, agarose- based protein A resins will remain the dominant type of matrix in the global protein A resins market, attributing to more than 80% of global revenues, according to Future Market Insights.
More information on the report can be availed at www.futuremarketinsights.com/reports/sample/rep-gb-1720
This post has been seen 155 times.